C3896862||F901318
C0456387||class
C0003308||antifungal drug
C0058099||dihydroorotate dehydrogenase
C0003308||antifungal agents
C0087111||treat
C2360800||number of patients
C2826244||life-threatening
C0553576||systemic fungal disease
C0033213||problem
C1514892||resistance
C2827774||current therapies
C3896862||F901318
C0456387||class
C1254351||drug
C1254351||orotomides
C0003308||antifungal drug
C1512068||clinical development
C1562222||dimorphic
C0369241||filamentous fungi
C0806957||susceptibility testing
C3896862||F901318
C0004034||Aspergillus spp
C1304747||minimal inhibitory concentrations
C0003235||antifungal
C0456387||classes
C0220825||investigation
C3896862||F901318
C0034289||pyrimidine
C0058099||enzyme dihydroorotate dehydrogenase
C0058099||dihydroorotate dehydrogenase
C0016832||fungal
C1512489||Homology modeling
C0004037||Aspergillus fumigatus
C0058099||dihydroorotate dehydrogenase
C0002520||amino acid residues
C0026809||murine
C0024109||pulmonary
C0004030||aspergillosis
C3896862||F901318
C1515655||in vivo
C0004037||A. fumigatus
C0004504||azole
C0456387||class
C0003235||antifungals
C0004504||azole
C3896862||F901318
C0008976||clinical trials
C0003235||antifungal
C0205229||expanded
C0456387||class
C0003308||agent
C0003235||antifungals